Check out share price calculations below..I believe Therma is considerably undervalued in the marketplace today. 10,000 units per year of Venowave would likely generate a gp of 1 million based on gp of 100 per unit on an assumed sell out price to DME of 200-250 per unit. Assume full dilution of 300 million units and a P to E of 20 (in line for tech and medical companies) gets you a share price of 6 cents. I think once production and logistic bottlenecks are resolved 100,000 units per year could easily be moved in the US alone leading to an Enterprise value of 60 cents. Notice how I valued all other devices including Acuvid at zero. In a country like the US the potential size of this Venowave is likely 5-10 million units per year based on a rapidly aging population. Let me be a bit self indulgent for a sec: 10 million units at 100 gp is 1 billion per year in total margin. Long story short when someone quote a Morningstar fair value of 51 cents I can easily see how an analyst came up to that number. At this point in time I also now see why Rob Fia made a comment in one of his recent YouTube videos that the market is discounting the potential of Venowave. Enjoy your Sunday everyone.